



Biosimilar medicines subsidised on the Pharmaceutical Benefits Scheme (PBS)

Active ingredient	Therapeutic Area Treated by Active Ingredient*	Reference brand (Sponsor)	Biosimilar brand (Sponsor)	Date of PBS listing for biosimilar brands
Epoetin lambda	Anaemia Chronic kidney failure	Eprex® brand of epoetin alfa (Janssen-Cilag)	Novicrit® (Sandoz)	01/08/2010 (pre-dated current PBAC approach to advice on 'a' flagging)
Filgrastim	Haematopoietic stem cell transplantation Chemotherapy induced neutropenia	Neupogen® (Amgen) 'a' flagged (note this brand is no longer available on the PBS)	Nivestim® (Pfizer) 'a' flagged	01/04/2011
			Zarzio® (Sandoz) 'a' flagged	01/09/2013
Infliximab	Ankylosing spondylitis Crohn's disease Psoriatic arthritis Psoriasis Rheumatoid arthritis Ulcerative colitis	Remicade® (Janssen- Cilag) 'a' flagged	Inflectra® (Pfizer) 'a' flagged	01/12/2015
			Renflexis® (Merck Sharp and Dohme) 'a' flagged	01/08/2017
			Ixifi® (Pfizer) 'a' flagged	1/11/ 2025
			Remsima® (Celltrion) 'a' flagged	1/07/2021
Follitropin alfa	Infertility treatment	Gonal-f® (Merck Serono Australia)	Bemfola® (Gedeon Richter)	01/08/2016
			Ovaleap® (Theramex) 'a' flagged	01/12/2021
Etanercept	Ankylosing spondylitis Psoriatic arthritis Psoriasis Rheumatoid arthritis Juvenile idiopathic arthritis	Enbrel® (Pfizer) 'a' flagged	Brenzys® (Merck Sharp and Dohme) 'a' flagged	01/04/2017
			Nepexto® (Alphapharm) 'a' flagged	01/07/2025
			Erelzy® (Sandoz) 'a' flagged	1/10/2025
Trastuzumab†	Breast cancer Gastric cancer	Herceptin® (Roche) (note this brand (IV) is no longer	Ogivri® (Alphapharm)	01/08/2019
			Herzuma® (Celltrion)	01/11/2019

Active ingredient	Therapeutic Area Treated by Active Ingredient*	Reference brand (Sponsor)	Biosimilar brand (Sponsor)	Date of PBS listing for biosimilar brands
		available on the PBS)	Kanjinti® (Amgen)	01/12/2019
			Trazimera® (Pfizer)	01/05/2020
Rituximab†	CD20 positive follicular B-cell non-Hodgkin's lymphoma Severe active granulomatosis with polyangiitis (Wegeners granulomatosis) CD20 positive non-Hodgkin's lymphoma Low-grade B-cell non-Hodgkin's lymphoma Chronic lymphocytic leukaemia Severe active rheumatoid arthritis Severe active microscopic polyangiitis	MabThera® (Roche) 'a' flagged (note this brand is no longer available on the PBS)	Riximyo® (Sandoz) 'a' flagged (s100) Truxima® (Celltrion) 'a' flagged (s100) Ruxience® (Pfizer) 'a' flagged (s100)	01/10/2019 01/01/2020 01/06/2022
Pegfilgrastim	Haematopoietic stem cell transplantation Chemotherapy induced neutropenia	Ristempa® (Juno) 'a' flagged (note this brand is no longer available on the PBS)	Ziextenzo® (Sandoz) 'a' flagged Pelgraz® (Accord) 'a' flagged	01/03/2020 01/08/2020
Adalimumab	Severe Crohn disease Moderate to severe ulcerative colitis Severe active juvenile idiopathic arthritis Complex refractory fistulising Crohn disease Severe active rheumatoid arthritis Severe psoriatic arthritis Ankylosing spondylitis Severe chronic plaque psoriasis Moderate to severe hidradenitis suppurativa	Humira® (AbbVie) 'a' flagged	Amgevita® (Amgen) 'a' flagged Hadlima® (Arrow Pharma) 'a' flagged Hyrimoz® (Sandoz) 'a' flagged Yuflyma® (Celltrion) 'a' flagged Abrilada® (Pfizer) 'a' flagged	01/04/2021 01/04/2021 01/04/2021 01/03/2023 01/08/2024

Active ingredient	Therapeutic Area Treated by Active Ingredient*	Reference brand (Sponsor)	Biosimilar brand (Sponsor)	Date of PBS listing for biosimilar brands
Bevacizumab†	Vision threatening non-infectious uveitis	Avastin® (Roche) (note this brand is no longer available on the PBS)	Mvasi® (Amgen)	01/06/2021
	Metastatic colorectal cancer Stage IV (metastatic) non-small cell lung cancer (NSCLC)		Abevmy® (Alphapharm)	01/12/2022
	Relapsed or recurrent glioblastoma Stage IIIB, IIIC or Stage IV epithelial ovarian, fallopian tube or primary peritoneal cancer Advanced carcinoma of cervix		Vegzelma® (Celltrion)	01/10/2024
Teriparatide	Osteoporosis in postmenopausal women; Primary osteoporosis in men when other agents are considered unsuitable and when there is a high risk of fracture; and Osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at high risk for fracture.	Forteo® (Eli Lilly) (note this brand is no longer available on PBS)	Terrosa® (Gedeon Richter)	01/10/2021
			Teriparatide Lupin® (Generic Health)	01/05/2024
Enoxaparin sodium	Prevention of thrombo-embolic disorders	Clexane® Clexane Forte® (sanofi-aventis) 'a' flagged	Exarane® Exarane Forte® (Juno) 'a' flagged	01/11/2023
Ustekinumab	Severe Crohn disease; moderate to severe ulcerative colitis; complex refractory Fistulising Crohn disease; severe psoriatic arthritis; and severe chronic plaque psoriasis.	Stelara® (Janssen-Cilag) 'a' flagged	Steqeyma® (Celltrion) 'a' flagged	1/08/2025

Active ingredient	Therapeutic Area Treated by Active Ingredient*	Reference brand (Sponsor)	Biosimilar brand (Sponsor)	Date of PBS listing for biosimilar brands
Omalizumab	Uncontrolled severe asthma; severe chronic spontaneous urticaria; uncontrolled severe allergic asthma;	Xolair® (Novartis) 'a' flagged	Omlyclo® (Celltrion) 'a' flagged	1/08/2025
Denosumab	Osteoporosis	Prolia® (Amgen) 'a' flagged	Jubbonti® (Sandoz) 'a' flagged	1/08/2025
			CORORA® (Amgen) 'a' flagged	1/09/2025
	Giant cell tumour of bone; Bone metastases.	Xgeva® (Amgen) 'a' flagged	Wyost® (Sandoz) 'a' flagged	1/08/2025
			GANVADO® (Amgen) 'a' flagged	1/09/2025
Aflibercept	Diabetic macular oedema: Subfoveal choroidal neovascularisation (CNV); Branch retinal vein occlusion with macular oedema	Eylea® (Bayer)	Afqilir® (Sandoz)	1/02/2026

Data correct as 1 February 2026.

* Refer to the Schedule of Pharmaceutical Benefits to identify indications for which the reference brand and biosimilar brand are available for subsidised access (all brands may not be available for all indications).

† The independent expert Pharmaceutical Benefits Advisory Committee (PBAC) recommended brands as substitutable biosimilars of the reference brands for the purposes of the Efficient Funding of Chemotherapy Program. Under section 33(2) of the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011, chemotherapy medicines supplied under the Efficient Funding of Chemotherapy Program may be substituted with a different brand of the same chemotherapy medicine. These medicines are not marked with 'a'-flags in the Schedule of Pharmaceutical Benefits.